Indiana-based Eli Lilly is making the single biggest U.S. investment in synthetic medicine manufacturing at a new state business park in Lebanon, Ind.
The campus will comprise 600 acres and begin production in 2026, “scaling up” through 2028, according to a company release. The corporation declined further comment. The investment will expand Lilly’s ability to manufacture active pharmaceutical ingredients for Zepbound injection and Mounjaro injection. These drugs are for adults with chronic diseases like obesity and Type 2 diabetes.Not only is this the largest investment in synthetic drug manufacturing but it’s Lilly’s largest investment ever.
Indiana Gov. Eric Holcomb said the state attributes the investment to its “leadership” in developing sites like the LEAP Research and Innovation District.
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: YahooFinanceCA - 🏆 47. / 63 اقرأ أكثر »